SEARCH

SEARCH BY CITATION

References

  • 1
    Ohga T, Koike K, Ono M et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 42248.
  • 2
    Kohno K, Uchiumi T, Niina I et al. Transcription factors and drug resistance. Eur J Cancer 2005; 41: 257786.
  • 3
    Torigoe T, Izumi H, Ishiguchi H et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005; 5: 1527.
  • 4
    Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 185565.
  • 5
    Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 59706.
  • 6
    Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 22735.
  • 7
    Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002; 38: 140512.
  • 8
    McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005; 14: 103346.
  • 9
    Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem Pharmacol 2008; 76: 5361.
  • 10
    Chollet P, Bensmaïne MA, Brienza S et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 106570.
  • 11
    Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 923.
  • 12
    Martinez-Balibrea E, Plasencia C, Ginés A et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 2009; 8: 7718.
  • 13
    Samimi G, Manorek G, Castel R et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 2005; 55: 111.
  • 14
    Hector S, Nava ME, Clark K, Murphy M, Pendyala L. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett 2007; 245: 195204.
  • 15
    Yang J, Parsons J, Nicolay NH et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010; 29: 4638.
  • 16
    Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 2005; 14: 92532.
  • 17
    Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006; 29: 22535.
  • 18
    Benedetti V, Perego P, Luca Beretta G et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008; 7: 67987.
  • 19
    Ekblad L, Kjellström J, Johnsson A. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs 2010; 21: 52331.
  • 20
    Martelli L, Ragazzi E, Di Mario F, Basato M, Martelli M. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency. Anticancer Res 2009; 29: 39317.
  • 21
    Igarashi T, Izumi H, Uchiumi T et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26: 474960.
  • 22
    Tanabe M, Izumi H, Ise T et al. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 2003; 63: 85925.
  • 23
    Shiota M, Izumi H, Onitsuka T et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68: 98105.
  • 24
    Miyamoto N, Izumi H, Noguchi T et al. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008; 283: 1821826.
  • 25
    Wakasugi T, Izumi H, Uchiumi T et al. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26: 5194203.
  • 26
    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 120914.
  • 27
    Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 181825.
  • 28
    Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998; 27: 187201.
  • 29
    Gronostajski RM. Site-specific DNA binding of nuclear factor I: effect of the spacer region. Nucleic Acids Res 1987; 15: 554559.
  • 30
    Ise T, Nagatani G, Imamura T et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59: 3426.
  • 31
    Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009; 1: 28091.
  • 32
    Uramoto H, Izumi H, Nagatani G et al. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 2003; 371: 30110.
  • 33
    Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol 2007; 373: 112340.